HCPLive Network

H. pylori Status May Affect Recurrent Ulcer Bleeding in Aspirin Users

THURSDAY, March 28 (HealthDay News) -- Risk of recurrent ulcer bleeding is low in long-term low-dose aspirin (ASA) users with a history of ulcer bleeding and eradication of Helicobacter pylori (H. pylori), but high in ASA users with a history of ulcer bleeding and negative for H. pylori, according to research published in the March issue of Gastroenterology.

Francis K.L. Chan, MD, of the Chinese University of Hong Kong, and colleagues conducted a prospective study to compare the incidence of recurrent ulcer bleeding in three different cohorts of patients: ASA users with a history of ulcer and eradication of H. pylori, ASA users with a history of ulcer and negative for H. pylori, and new ASA users with no history of ulcer and unknown H. pylori status.

According to the researchers, the incidence rate of ulcer bleeding in the H. pylori-eradicated cohort was similar to that found in the new ASA users cohort (0.97 per 100 patient-years [95 percent confidence interval, 0.53 to 1.80] and 0.66, respectively). In contrast, the H. pylori-negative cohort had the highest incidence of recurrent bleeding (5.22). The incidence of ulcer bleeding was five times higher than that found in the H. pylori-eradicated cohort and eight times higher than that found in the new ASA users cohort.

"ASA users who developed ulcer bleeding without current or past H. pylori infection are at high risk of recurrent bleeding," the authors write. "Our study provides novel data to guideline committees to refine their treatment recommendations for ASA users who are at risk of ulcer bleeding."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
Experimental drug RHB-105, a fixed-dose combination therapy of two antibiotics and a proton pump inhibitor, will be tested in patients with confirmed H. pylori infection.
Long-term use of low-dose aspirin (LDA) is associated with increased risk of developing peptic ulcers in patients without a previous history of the condition.
With 10% of Americans contracting ulcers, pharmacists can be a valuable source of education for patients regarding the causes of peptic ulcer and the pros and cons of available treatments.
Patients on antithrombotic therapy must be monitored for increased risk of upper GI bleeding.
German biotech firms are working a formulation for IMX101, a multicomponent recombinant vaccine against Helicobacter pylori, a bacterium linked to gastric ulcers.
Study supports the current practice of post-surgery H. pylori eradication in patients with perforated peptic ulcers.
Study results suggest that formulary exclusion of esomeprazole with the intent to cut costs may actually lead to substantially higher healthcare utilization and medical and prescription costs.
More Reading